NASDAQ:CAPR

Capricor Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CAPR

*Your capital is at risk

$29.60

+0.260 (+0.89%)

At Close: Jun 23, 2026

Capricor Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -62.36. In total, the insiders bought 1.69M and sold 252.62K CAPR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-62.36
● Buy	1.69M shares
● Sell	252.62K shares
89% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Mar 31, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -62.36. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Maurer Michael T Chief Commercial Officer	Officer	80 000 Value: $2.35M
May 25, 2026 Buy	Common Stock J-Other	Maurer Michael T Insider	Other	0 Value: $0
May 18, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Bergmann Anthony Chief Financial Officer	C-Suite Officer	3 000 Value: $4K
May 18, 2026 Buy	Common Stock M-Exempt	Bergmann Anthony Chief Financial Officer	C-Suite Officer	3 000 Value: $4K
May 13, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Litvack Frank Director	Director	3 937 Value: $5K
May 13, 2026 Buy	Common Stock M-Exempt	Litvack Frank Director	Director	3 937 Value: $5K
May 01, 2026 Sell	Common Stock S-Sale	Bergmann Anthony Chief Financial Officer	C-Suite Officer	25 000 Value: $792.5K
May 01, 2026 Buy	Common Stock M-Exempt	Bergmann Anthony Chief Financial Officer	C-Suite Officer	25 000 Value: $79.5K
May 01, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Bergmann Anthony Chief Financial Officer	C-Suite Officer	25 000 Value: $79.5K
May 01, 2026 Sell	Common Stock S-Sale	Krasney Karen EVP, General Counsel	Officer	25 000 Value: $792.5K
May 01, 2026 Buy	Common Stock M-Exempt	Krasney Karen EVP, General Counsel	Officer	25 000 Value: $79.5K
May 01, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Krasney Karen EVP, General Counsel	Officer	25 000 Value: $79.5K
Apr 02, 2026 Sell	Common Stock S-Sale	Sabar Karimah Es Director	Director	7 529 Value: $240.9K
Apr 02, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Sabar Karimah Es Director	Director	7 529 Value: $23.9K
Apr 02, 2026 Buy	Common Stock M-Exempt	Sabar Karimah Es Director	Director	7 529 Value: $23.9K
Apr 01, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Sabar Karimah Es Director	Director	53 735 Value: $261.2K
Apr 01, 2026 Buy	Common Stock M-Exempt	Sabar Karimah Es Director	Director	53 735 Value: $261.2K
Apr 01, 2026 Sell	Common Stock S-Sale	Sabar Karimah Es Director	Director	53 735 Value: $1.67M
Mar 31, 2026 Sell	Common Stock S-Sale	Bergmann Anthony Chief Financial Officer	C-Suite Officer	25 000 Value: $753.2K
Mar 31, 2026 Buy	Common Stock M-Exempt	Bergmann Anthony Chief Financial Officer	C-Suite Officer	25 000 Value: $79.5K
Mar 31, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Bergmann Anthony Chief Financial Officer	C-Suite Officer	25 000 Value: $79.5K
Mar 31, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Krasney Karen EVP, General Counsel	Officer	2 819 Value: $9K
Mar 31, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Krasney Karen EVP, General Counsel	Officer	21 488 Value: $80.4K
Mar 31, 2026 Buy	Common Stock M-Exempt	Krasney Karen EVP, General Counsel	Officer	2 819 Value: $9K
Mar 31, 2026 Buy	Common Stock M-Exempt	Krasney Karen EVP, General Counsel	Officer	21 488 Value: $80.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CAPRICOR THERAPEUTICS

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph...

Read Full Profile Here